Meta Pixel

News and Announcements

GDTC Welcomes Increased Investment from MTAQ

  • Published February 16, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Green Distillation Technologies (GDTC), who has developed a proprietary process to convert End of Life Tyres (ELT) into the saleable commodities of carbon, oil and steel, profitably, with no waste and a negative carbon footprint, have recently revised their capital raising opportunity and welcomed MTAQ – the Motor Trades Association of Queensland in committing a further $1.5m in the current raise of $5m at a discounted equity price. 

In addition to the Australian Government legislation, which bans the export of whole baled tyres, it was announced in January 2022 that the Indian Government plans to prohibit the import of waste tyres destined for pyrolysis plants. This is a significant initiative that will affect the international waste tyre market but it will also further add to the volumes that will require processing here in Australia. This is a real positive for GDTC.

The capital will be used to expand their Warren plant to 50% capacity and be able to operate 24/7 and generate revenues from tyre disposal fees, and the off-take products of oil, carbon and steel. A further raise via IPO will be held in 2023. 

Further information on the revised offer can be obtained in the CRIISPTM deal room.

Learn more about the GDT process by watching this video here

Register Interest

About Green Distillation Technologies

Green Distillation Technologies (GDT) is an Australian company that has developed and proven a proprietary process that converts end of life tyres into 3 saleable commodities of carbon, oil and steel. In Australia 26 million waste tyres are generated each year and if discarded will take at least 300 years to biodegrade. In 2020 Tyre Stewardship Australia estimated that 71% of ‘on road’ waste tyres were exported. In December 2021, the Federal Government ban on exporting waste tyres will see the doubling of volumes to be processed in Australia.

Register Interest

Capital Insights
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t

The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.

Capital Insights
Following the Billions: Where the Hyperscalers are Betting on the Future

The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.

Join over 45,000+ sophisticated investors

Join Now